Abstract
Objective: Evaluate if the clinical measures SNOT-22 and UPSIT are efficient in monitoring treatment in Brazilian patients with CRS.
Method: A total of 16 patients with CRS were treated with topical mometasone (200 microgram BID) for 2 months. SNOT-22, sense of smell score in SNOT-22, UPSIT, Lund-Mackay (for CT) and Lund (for endoscopy) scores were evaluated before and after treatment. Multi-variable correlation tests were used to compare the differences between scales.
Results: Improvement in UPSIT scores correlated negatively to the sense of smell score in SNOT-22, (R2: 0.50; P = .0367), demonstrating to be a good tool to quantify smell problems. On the contrary, UPSIT did not correlate with CT and endoscopy scores. Improvement in SNOT-22 scores correlated significantly to improvement in endoscopy scores (R2: 0.49; P = .0297), but not to CT and UPSIT scores.
Conclusion: UPSIT is a valuable tool to measure smell changes and monitor the effect of clinical treatment in patients with CRS. SNOT-22 correlated positively to intranasal polyp formation rather than sinusal opacity on CT scans.
Get full access to this article
View all access options for this article.